top of page

Mitsubishi Electric Buys Out Poland's Medcom in European Rail Supply-Chain Push

Aug 14
2 min read

Mitsubishi Electric has agreed to take full ownership of Medcom, one of Europe's leading manufacturers of power electronics for rail vehicles, in a deal that tightens Japanese control over a strategic node of the continent's rolling-stock supply chain and signals foreign confidence in what the buyer calls the world's largest rail market.


The Japanese group announced on 7 August that it would acquire the remaining 51 per cent stake in the Warsaw-based company through its wholly owned subsidiary Mitsubishi Electric Europe, giving it 100 per cent ownership after a decade as minority shareholder. The transaction, whose value was not disclosed, is subject to regulatory approvals and is expected to complete by the end of September. Mitsubishi Electric first took a 49 per cent holding in Medcom in 2016, and the buyout deepens a partnership built around the group's silicon carbide power devices.


Medcom's reach across European transport is considerable. The firm designs, manufactures and maintains auxiliary power supply systems, propulsion control equipment and industrial power electronics that run in mainline and urban rolling stock across the continent, as well as in battery-electric buses and trolleybuses. It is a key supplier to Polish trainmaker Newag and to bus manufacturer Solaris, whose electric and hydrogen fleets and Trollino trolleybuses use its drive systems, placing the company at the heart of Central European vehicle production.


The strategic logic is explicit. Mitsubishi Electric said full ownership would let it integrate group resources and accelerate decision-making, and set out plans to make Warsaw its European centre of excellence for research, engineering and manufacturing of energy-efficient power electronics. Executive officer Hideto Negoro framed the move as preserving Medcom's entrepreneurial character while expanding its capabilities in one of the world's most technologically demanding markets.


Medcom has sought to reassure the domestic market that it will continue as a separate legal entity under its own name and management, a common sensitivity where a national champion passes into foreign hands. The deal nonetheless fits a wider pattern of consolidation rippling through the European rail supply base, as component makers seek the scale, capital and technology needed to serve a continent embarking on record rolling-stock renewal and digital signalling investment.

Comments


Top Stories

bottom of page